SecBot SecBot
424B56-K ·Filed Apr 9, 2026

SXTC

China SXT Pharmaceuticals, Inc.
BEARISH
Impact 6/10
Horizonimmediate Processed6mo ago SEC0001213900-26-041766
Actionable Insight ▼ Bearish

The substantial discount to market price and significant dilution suggest the company may be facing financial pressure. Investors should be cautious as this dilutive financing at a steep discount typically indicates weak negotiating position and could pressure the stock price further.

DirectionBearish
Confidencehigh
Horizonimmediate
Final — all horizons settled through T+60d
SXTC ▲ +15.46% at T+60d
SHORT call ✗ call lost -15.46% · α vs SPY -4.68% · entry $2.07 → $2.39
Entry = T+0 close
Apr 9, 2026
via day close
T+1d
+12.08%
call -12.08% · α -12.14%
$2.32
settled 7mo ago
T+5d
-6.91%
call +6.91% · α +10.09%
$1.93
settled 6mo ago
T+20d
-14.98%
call +14.98% · α +22.54%
$1.76
settled 6mo ago
T+60d
+15.46%
call -15.46% · α -4.68%
$2.39
settled 4mo ago

Price Chart

Loading chart...

Executive Summary

China SXT Pharmaceuticals is raising $760,000 through a direct placement of 2 million Class A ordinary shares at $0.38 per share, significantly below the $2.07 market price on the offering date. The proceeds will be used for working capital and general corporate purposes, but the transaction results in substantial dilution for existing shareholders.

Key Facts

  • Offering of 2,000,000 Class A Ordinary Shares at $0.38 per share
  • Gross proceeds of $760,000 from the offering
  • Offering price is 81.6% below the $2.07 market price on April 7, 2026
  • Significant dilution with net tangible book value decreasing from $30.62 to $10.17 per share
  • Proceeds to be used for working capital and general corporate purposes

Financial Impact

$760,000 raised at $0.38 per share, representing significant dilution

dilutionmarket capitalizationbook value

Risk Factors

  • Significant shareholder dilution
  • Large discount to market price signaling financial distress
  • Proceeds used for general working capital rather than specific growth initiatives
  • Potential for further dilutive offerings

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
424B5 Filing (SXTC) — Batch item 10001213900-26-041766
Document: 0001213900-26-041766-index-headers.html0001213900-26-041765
Document: 0001213900-26-041766-index.html0001213900-26-041766
Document: 0001213900-26-041766.txt0001213900-26-041766
6-K Filing (SXTC) — Batch item 50001213900-26-041765
13 reports for SXTC
Performance horizon
78% Hit rate @ T+5 7 of 9 directional calls Went positive at some point 9 of 10 best @ T+20▲ +97.17%Sep 17, 2026
Filters
Rows
Reports for SXTC — sortable, filterable
TypeNow
Oct 21, 2026
4d ago
6-K
BULLISH ★ 4/10
$0.0480awaiting T+5——
Oct 15, 2026
10d ago
SC 13G
NEUTRAL ★ 3/10
$0.0650 $0.0410▼ −36.92%▼ −36.49%—
Oct 9, 2026
16d ago
6-K
BEARISH ★ 7/10
$0.1020 $0.1112▼ −9.02%▼ −10.51%—
Oct 9, 2026
17d ago
424B5
BEARISH ★ 7/10
$0.1487 $0.0650▲ +56.29%▲ +54.32%—
Oct 8, 2026
18d ago
6-K
BEARISH ★ 6/10
$0.3435 $0.0688▲ +79.97%▲ +79.69%—
Oct 8, 2026
18d ago
6-K
BEARISH ★ 5/10
$0.3435 $0.0688▲ +79.97%▲ +79.69%—
Sep 17, 2026
5w ago
EFFECT
BEARISH ★ 5/10
$2.44 $2.55▼ −4.72%▼ −4.12%—
Aug 28, 2026
8w ago
6-K
BEARISH ★ 8/10
$2.56 $2.24▲ +12.50%▲ +12.36%—
Jul 24, 2026
13w ago
424B5
BEARISH ★ 8/10
$0.0638 $0.0618▲ +3.13%▲ +4.23%—
Jun 1, 2026
20w ago
424B5
BEARISH ★ 7/10
$1.78 $1.56▲ +12.36%▲ +9.39%—
Showing 10 of 13

US Market Status

Market Closed — Opens Tue (17h 29m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 9, 2026